1
|
Schwartz K, Zhang M, Franco B, Jampachaisri K, Cotton RM, Huss MK, Fisher KM, Darian-Smith C, Sharp P, Pablo L, Pacharinsak C. Effects of atipamezole on selected physiologic parameters in cynomolgus macaques (Macaca fascicularis). J Med Primatol 2024; 53:e12682. [PMID: 37908039 DOI: 10.1111/jmp.12682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Accepted: 10/09/2023] [Indexed: 11/02/2023]
Abstract
BACKGROUND Atipamezole, an α-2 adrenergic receptor antagonist, reverses the α-2 agonist anesthetic effects. There is a dearth of information on the physiological effects of these drugs in cynomolgus macaques (Macaca fascicularis). We assessed atipamezole's physiologic effects. We hypothesized atipamezole administration would alter anesthetic parameters. METHODS Five cynomolgus macaques were sedated with ketamine/dexmedetomidine intramuscularly, followed 45 min later with atipamezole (0.5 mg/kg). Anesthetic parameters (heart rate, blood pressure [systolic (SAP), diastolic (DAP), and mean (MAP) blood pressure], body temperature, respiratory rate, and %SpO2) were monitored prior to and every 10 min (through 60 min) post atipamezole injection. RESULTS While heart rate was significantly increased for 60 min; SAP, DAP, MAP, and temperature were significantly decreased at 10 min. CONCLUSIONS This study indicates subcutaneous atipamezole results in increased heart rate and transient blood pressure decrease. These findings are clinically important to ensure anesthetist awareness to properly support and treat patients as needed.
Collapse
Affiliation(s)
- K Schwartz
- Department of Comparative Medicine, Stanford University, Stanford, California, USA
| | - M Zhang
- Department of Comparative Medicine, Stanford University, Stanford, California, USA
| | - B Franco
- Department of Comparative Medicine, Stanford University, Stanford, California, USA
| | - K Jampachaisri
- Department of Mathematics, Naresuan University, Phitsanulok, Thailand
| | - R M Cotton
- Department of Comparative Medicine, Stanford University, Stanford, California, USA
| | - M K Huss
- Department of Comparative Medicine, Stanford University, Stanford, California, USA
| | - K M Fisher
- Department of Comparative Medicine, Stanford University, Stanford, California, USA
| | - C Darian-Smith
- Department of Comparative Medicine, Stanford University, Stanford, California, USA
| | - P Sharp
- University of California, Merced, California, USA
- Murdoch University, Murdoch, Western Australia, Australia
| | - L Pablo
- Department of Comparative, Diagnostic & Population Medicine, University of Florida College, Gainesville, Florida, USA
| | - C Pacharinsak
- Department of Comparative Medicine, Stanford University, Stanford, California, USA
| |
Collapse
|
2
|
Schwartz K, Beebe-Dimmer J, Hastert TA, Ruterbusch JJ, Mantey J, Harper F, Thompson H, Pandolfi S, Schwartz AG. Caregiving burden among informal caregivers of African American cancer survivors. J Cancer Surviv 2021; 15:630-640. [PMID: 33067774 PMCID: PMC8052386 DOI: 10.1007/s11764-020-00956-x] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Accepted: 10/10/2020] [Indexed: 12/12/2022]
Abstract
PURPOSE Relatively little is known about caregivers of African American cancer survivors. Our goal was to identify the extent of burden among this group of caregivers. METHODS Responses from 560 informal caregivers of African American participants of the Research on Cancer Survivors (ROCS) study in Detroit, MI, were analyzed including demographics, assistance provided including activities of daily living (ADLs) and instrumental activities of daily living (IADLs), time spent in caregiving, and caregiver burden (CGB). We assessed relationships between CGB and demographic variables, ADLs/IADLs, and level of care. Multivariable logistic regression determined which ADLs and IADLs were associated with high CGB. RESULTS Over 75% of caregivers were female and 97% identified as African American. Mean age was 52.6 years. Fifty-six percent were employed outside the home, and 90% were related to the survivor. Caregivers averaged 35.7 h/week providing care, assisting with on average 2.8 ADLs and 5.0 IADLs. Despite the many hours and activities reported, no caregivers rated CGB as severe; only 4% rated it moderate to severe. ADLs associated with the top quartile of CGB were feeding and toileting; IADLs were finances, telephoning, housework, and medications. CONCLUSIONS Caregivers for African American cancer survivors provide many hours of care, yet most describe their CGB as low. Although ADL assistance is often available through the healthcare system, assistance with IADLs presents an opportunity to lessen the burden for these caregivers and their care recipients. IMPLICATIONS FOR CANCER SURVIVORS African American cancer survivors receive much care from informal family caregivers, who assist with multiple ADLs and IADLs. Formal IADL assistance programs, similar to those available for ADLs, would benefit both survivors and caregivers.
Collapse
Affiliation(s)
- K Schwartz
- Department of Family Medicine and Public Health Sciences, Wayne State University School of Medicine, Detroit, MI, USA.
- Population Studies and Disparities Research Program, Karmanos Cancer Institute, Wayne State University, 87 E. Canfield, Detroit, MI, 48201, USA.
| | - J Beebe-Dimmer
- Population Studies and Disparities Research Program, Karmanos Cancer Institute, Wayne State University, 87 E. Canfield, Detroit, MI, 48201, USA
- Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA
| | - T A Hastert
- Population Studies and Disparities Research Program, Karmanos Cancer Institute, Wayne State University, 87 E. Canfield, Detroit, MI, 48201, USA
- Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA
| | - J J Ruterbusch
- Population Studies and Disparities Research Program, Karmanos Cancer Institute, Wayne State University, 87 E. Canfield, Detroit, MI, 48201, USA
| | - J Mantey
- Population Studies and Disparities Research Program, Karmanos Cancer Institute, Wayne State University, 87 E. Canfield, Detroit, MI, 48201, USA
- Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA
| | - F Harper
- Population Studies and Disparities Research Program, Karmanos Cancer Institute, Wayne State University, 87 E. Canfield, Detroit, MI, 48201, USA
- Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA
- Office of Cancer Health and Community Engagement, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
| | - H Thompson
- Population Studies and Disparities Research Program, Karmanos Cancer Institute, Wayne State University, 87 E. Canfield, Detroit, MI, 48201, USA
- Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA
- Office of Cancer Health and Community Engagement, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
| | - S Pandolfi
- Population Studies and Disparities Research Program, Karmanos Cancer Institute, Wayne State University, 87 E. Canfield, Detroit, MI, 48201, USA
| | - A G Schwartz
- Population Studies and Disparities Research Program, Karmanos Cancer Institute, Wayne State University, 87 E. Canfield, Detroit, MI, 48201, USA
- Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA
| |
Collapse
|
3
|
Caldwell J, Sepulveda J, Ghosh P, Delp M, Wahl J, Restrepo A, Morgan H, Ulrich B, Patterson N, Rosenthal S, Vega‐Figueroa L, Sadowsky D, McKinley‐Caspanello C, Schwartz K, Muller‐Delp J. Adiponectin‐deficient Mice Demonstrate Impaired Coronary Arteriolar Vasodilation and Subsequent Decline in Cardiac Function. FASEB J 2019. [DOI: 10.1096/fasebj.2019.33.1_supplement.833.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | | | | | | | - J Wahl
- Florida State UniversityTallahasseeFL
| | | | - H Morgan
- Florida State UniversityTallahasseeFL
| | - B Ulrich
- Florida State UniversityTallahasseeFL
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Bagla S, Levy J, Hopkins T, Massari F, Vogel A, Bress A, Dixon R, Mitchell J, Sunenshine P, Barr J, Tran N, Morris J, Berrier H, Brelje T, Schwartz K. Abstract No. 618 Rapid pain improvement in patients treated for painful bone metastases with the Medtronic Osteocool RF Ablation system: the OPuS One study. J Vasc Interv Radiol 2019. [DOI: 10.1016/j.jvir.2018.12.723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
5
|
Gabler N, Helm E, DeMille C, Curry S, Schweer W, Lonergan S, Loving C, Schwartz K, Burrough E. 501 Immunometabolism responses to disease in pigs and its impact on feed efficiency. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- N Gabler
- Iowa State University,Ames, IA, United States
| | - E Helm
- Iowa State University,Ames, IA, United States
| | - C DeMille
- Iowa State University,Ames, IA, United States
| | - S Curry
- ORISE Postdoctoral Researcher, Oak Ridge, TN, United States
| | - W Schweer
- Iowa State University,Ames, IA, United States
| | - S Lonergan
- Iowa State University,Ames, IA, United States
| | - C Loving
- USDA-ARS-National Animal Disease Center,Ames, IA, United States
| | - K Schwartz
- Iowa State University,Ames, IA, United States
| | - E Burrough
- Iowa State University,Ames, IA, United States
| |
Collapse
|
6
|
Battaglioli EJ, Goh KGK, Atruktsang TS, Schwartz K, Schembri MA, Welch RA. Identification and Characterization of a Phase-Variable Element That Regulates the Autotransporter UpaE in Uropathogenic Escherichia coli. mBio 2018; 9:e01360-18. [PMID: 30087170 PMCID: PMC6083910 DOI: 10.1128/mbio.01360-18] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Accepted: 06/28/2018] [Indexed: 12/15/2022] Open
Abstract
Uropathogenic Escherichia coli (UPEC) is the most common etiologic agent of uncomplicated urinary tract infection (UTI). An important mechanism of gene regulation in UPEC is phase variation that involves inversion of a promoter-containing DNA element via enzymatic activity of tyrosine recombinases, resulting in biphasic, ON or OFF expression of target genes. The UPEC reference strain CFT073 has five tyrosine site-specific recombinases that function at two previously characterized promoter inversion systems, fimS and hyxS Three of the five recombinases are located proximally to their cognate target elements, which is typical of promoter inversion systems. The genes for the other two recombinases, IpuA and IpuB, are located distal from these sites. Here, we identified and characterized a third phase-variable invertible element in CFT073, ipuS, located proximal to ipuA and ipuB The inversion of ipuS is catalyzed by four of the five CFT073 recombinases. Orientation of the element drives transcription of a two-gene operon containing ipuR, a predicted LuxR-type regulator, and upaE, a predicted autotransporter. We show that the predicted autotransporter UpaE is surface located and facilitates biofilm formation as well as adhesion to extracellular matrix proteins in a K-12 recombinant background. Consistent with this phenotype, the ipuS ON condition in CFT073 results in defective swimming motility, increased adherence to human kidney epithelial cells, and a positive competitive kidney colonization advantage in experimental mouse UTIs. Overall, the identification of a third phase switch in UPEC that is regulated by a shared set of recombinases describes a complex phase-variable virulence network in UPEC.IMPORTANCE Uropathogenic Escherichia coli (UPEC) is the most common cause of urinary tract infection (UTI). ON versus OFF phase switching by inversion of small DNA elements at two chromosome sites in UPEC regulates the expression of important virulence factors, including the type 1 fimbria adhesion organelle. In this report, we describe a third invertible element, ipuS, in the UPEC reference strain CFT073. The inversion of ipuS controls the phase-variable expression of upaE, an autotransporter gene that encodes a surface protein involved in adherence to extracellular matrix proteins and colonization of the kidneys in a murine model of UTI.
Collapse
Affiliation(s)
- E J Battaglioli
- Department of Medical Microbiology and Immunology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA
- Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
| | - K G K Goh
- School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, QLD, Australia
| | - T S Atruktsang
- Department of Medical Microbiology and Immunology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - K Schwartz
- Department of Medical Microbiology and Immunology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - M A Schembri
- School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, QLD, Australia
| | - R A Welch
- Department of Medical Microbiology and Immunology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA
| |
Collapse
|
7
|
Schweer W, Schwartz K, Patience JF, Karriker L, Sparks C, Weaver M, Fitzsimmons M, Burkey TE, Gabler NK. Porcine Reproductive and Respiratory Syndrome virus reduces feed efficiency, digestibility, and lean tissue accretion in grow-finish pigs. Transl Anim Sci 2017; 1:480-488. [PMID: 32704671 PMCID: PMC7204981 DOI: 10.2527/tas2017.0054] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Accepted: 09/08/2017] [Indexed: 11/30/2022] Open
Abstract
Porcine reproductive and respiratory syndrome (PRRS) virus is a major swine virus that causes reproductive impairment in sows, as well as respiratory disease, reduction in growth rates, and mortalities in all ages of pigs. The objective of this study was to quantify the impact PRRS has on grower-finisher pig feed efficiency and tissue accretion rates. Thirty PRRS naïve, littermate pairs of maternal line Choice Genetics gilts (33.6 ± 0.58 kg BW) were selected and pairs split across 2 barns consisting of 5 pens (n = 6 pigs/pen per barn). Pigs in both barns were fed corn-soybean-DDGS diets ad libitum. All pigs in one barn were inoculated (CHAL) via an i.m. injection of a live PRRS strain isolated from the region (0 d post inoculation, dpi), while pigs in the other barn were given a saline control injection (CONT). Pig performance (ADG, ADFI, G:F) was assessed from 35 kg BW until each group reached market BW (128 kg). Additionally, longitudinal apparent total tract digestibility (ATTD) and body composition was assessed using Dual-energy X-ray absorptiometry (DXA) post inoculation (dpi) to estimate lean, protein, fat and bone accretion rates. Serological data from CHAL pigs showed that PRRS titers peaked 7 dpi and these pigs seroconverted by 35 dpi. According to both genomic and protein PRRS titers, CONT pigs were naïve to CHAL throughout the study. The PRRS infection reduced (P < 0.001) ATTD of dry matter, energy and nitrogen by 3 to 5% at 21 dpi and the reduction in ATTD persisted after 65 dpi. Compared to the CONT, CHAL pigs had decreased ADG (0.89 vs. 0.80 kg/d, P < 0.001), ADFI (2.05 vs. 1.93 kg/d, P < 0.001), and G:F (0.44 vs. 0.41 kg/d, P < 0.001) over the entire test period. The CHAL pigs also had attenuated DXA predicted whole body accretion of lean (547 vs. 633 g/d, P = 0.001), protein (109 vs. 126 g/d, P = 0.001) and fat (169 vs. 205 g/d, P = 0.001) compared to their CONT counterparts from dpi 0 to 80. Based on carcass data at slaughter (and consistent with the DXA data), CHAL pigs had leaner carcasses and reduced yields. These data clearly demonstrate that PRRS infection reduces digestibility, feed efficiency and protein accretion rates in grower-finisher pigs.
Collapse
Affiliation(s)
- W Schweer
- Department of Animal Science, Iowa State University, Ames 50011
| | - K Schwartz
- Department of Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames 50011
| | - J F Patience
- Department of Animal Science, Iowa State University, Ames 50011
| | - L Karriker
- Department of Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames 50011
| | - C Sparks
- Huvepharma, Peachtree City, GA, 30269
| | - M Weaver
- Weaver Consulting, Des Moines, IA, 50265
| | | | - T E Burkey
- Department of Animal Science, University of Nebraska, Lincoln 68583
| | - N K Gabler
- Department of Animal Science, Iowa State University, Ames 50011
| |
Collapse
|
8
|
Uldrick TS, Ison G, Rudek MA, Noy A, Schwartz K, Bruinooge S, Schenkel C, Miller B, Dunleavy K, Wang J, Zeldis J, Little RF. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group. J Clin Oncol 2017; 35:3774-3780. [PMID: 28968173 PMCID: PMC5793223 DOI: 10.1200/jco.2017.73.7338] [Citation(s) in RCA: 106] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Purpose People with HIV are living longer as a result of effective antiretroviral therapy. Cancer has become a leading cause of morbidity and mortality in this patient population. However, studies of novel cancer therapeutics have historically excluded patients with HIV. Critical review of eligibility criteria related to HIV is required to accelerate development of and access to effective therapeutics for HIV-infected patients with cancer and make studies more generalizable to this patient population. Methods From January through April 2016, the HIV Working Group conducted a series of teleconferences; a review of 46 New Drug Applications from registration studies of unique agents studied in adults with cancer that led to the initial US Food and Drug Administration approval of that agent from 2011 to 2015; and a review of HIV-related eligibility criteria from National Cancer Institute-sponsored studies. Results were discussed and refined at a multistakeholder workshop held May 12, 2016. The HIV Working Group developed recommendations for eligibility criteria that focus on pharmacologic and immunologic considerations in this patient population and that balance patient safety, access to appropriate investigational agents, and study integrity. Results Exclusion of patients with HIV remains common in most studies of novel cancer agents. Models for HIV-related eligibility criteria in National Cancer Institute-sponsored studies are instructive. HIV infection itself should no longer be an exclusion criterion for most studies. Eligibility criteria related to HIV infection that address concurrent antiretroviral therapy and immune status should be designed in a manner that is appropriate for a given cancer. Conclusion Expanding clinical trial eligibility to be more inclusive of patients with HIV is justified in most cases and may accelerate the development of effective therapies in this area of unmet clinical need.
Collapse
Affiliation(s)
- Thomas S Uldrick
- Thomas S. Uldrick and Richard F. Little, National Cancer Institute, Bethesda; Gwynn Ison and Barry Miller, US Food and Drug Administration, Silver Spring; Michelle A. Rudek, Johns Hopkins University, Baltimore, MD; Ariela Noy, Memorial Sloan Kettering Cancer Center and Weill Medical College, New York, NY; Karl Schwartz, Patients Against Lymphoma, Riegelsville, PA; Suanna Bruinooge and Caroline Schenkel, ASCO, Alexandria, VA; Kieron Dunleavy, George Washington University, Washington, DC; Judy Wang, Florida Cancer Specialists and Research Institute, Sarasota, FL; and Jerome Zeldis, Sorrento Therapeutics, San Diego, CA
| | - Gwynn Ison
- Thomas S. Uldrick and Richard F. Little, National Cancer Institute, Bethesda; Gwynn Ison and Barry Miller, US Food and Drug Administration, Silver Spring; Michelle A. Rudek, Johns Hopkins University, Baltimore, MD; Ariela Noy, Memorial Sloan Kettering Cancer Center and Weill Medical College, New York, NY; Karl Schwartz, Patients Against Lymphoma, Riegelsville, PA; Suanna Bruinooge and Caroline Schenkel, ASCO, Alexandria, VA; Kieron Dunleavy, George Washington University, Washington, DC; Judy Wang, Florida Cancer Specialists and Research Institute, Sarasota, FL; and Jerome Zeldis, Sorrento Therapeutics, San Diego, CA
| | - Michelle A Rudek
- Thomas S. Uldrick and Richard F. Little, National Cancer Institute, Bethesda; Gwynn Ison and Barry Miller, US Food and Drug Administration, Silver Spring; Michelle A. Rudek, Johns Hopkins University, Baltimore, MD; Ariela Noy, Memorial Sloan Kettering Cancer Center and Weill Medical College, New York, NY; Karl Schwartz, Patients Against Lymphoma, Riegelsville, PA; Suanna Bruinooge and Caroline Schenkel, ASCO, Alexandria, VA; Kieron Dunleavy, George Washington University, Washington, DC; Judy Wang, Florida Cancer Specialists and Research Institute, Sarasota, FL; and Jerome Zeldis, Sorrento Therapeutics, San Diego, CA
| | - Ariela Noy
- Thomas S. Uldrick and Richard F. Little, National Cancer Institute, Bethesda; Gwynn Ison and Barry Miller, US Food and Drug Administration, Silver Spring; Michelle A. Rudek, Johns Hopkins University, Baltimore, MD; Ariela Noy, Memorial Sloan Kettering Cancer Center and Weill Medical College, New York, NY; Karl Schwartz, Patients Against Lymphoma, Riegelsville, PA; Suanna Bruinooge and Caroline Schenkel, ASCO, Alexandria, VA; Kieron Dunleavy, George Washington University, Washington, DC; Judy Wang, Florida Cancer Specialists and Research Institute, Sarasota, FL; and Jerome Zeldis, Sorrento Therapeutics, San Diego, CA
| | - Karl Schwartz
- Thomas S. Uldrick and Richard F. Little, National Cancer Institute, Bethesda; Gwynn Ison and Barry Miller, US Food and Drug Administration, Silver Spring; Michelle A. Rudek, Johns Hopkins University, Baltimore, MD; Ariela Noy, Memorial Sloan Kettering Cancer Center and Weill Medical College, New York, NY; Karl Schwartz, Patients Against Lymphoma, Riegelsville, PA; Suanna Bruinooge and Caroline Schenkel, ASCO, Alexandria, VA; Kieron Dunleavy, George Washington University, Washington, DC; Judy Wang, Florida Cancer Specialists and Research Institute, Sarasota, FL; and Jerome Zeldis, Sorrento Therapeutics, San Diego, CA
| | - Suanna Bruinooge
- Thomas S. Uldrick and Richard F. Little, National Cancer Institute, Bethesda; Gwynn Ison and Barry Miller, US Food and Drug Administration, Silver Spring; Michelle A. Rudek, Johns Hopkins University, Baltimore, MD; Ariela Noy, Memorial Sloan Kettering Cancer Center and Weill Medical College, New York, NY; Karl Schwartz, Patients Against Lymphoma, Riegelsville, PA; Suanna Bruinooge and Caroline Schenkel, ASCO, Alexandria, VA; Kieron Dunleavy, George Washington University, Washington, DC; Judy Wang, Florida Cancer Specialists and Research Institute, Sarasota, FL; and Jerome Zeldis, Sorrento Therapeutics, San Diego, CA
| | - Caroline Schenkel
- Thomas S. Uldrick and Richard F. Little, National Cancer Institute, Bethesda; Gwynn Ison and Barry Miller, US Food and Drug Administration, Silver Spring; Michelle A. Rudek, Johns Hopkins University, Baltimore, MD; Ariela Noy, Memorial Sloan Kettering Cancer Center and Weill Medical College, New York, NY; Karl Schwartz, Patients Against Lymphoma, Riegelsville, PA; Suanna Bruinooge and Caroline Schenkel, ASCO, Alexandria, VA; Kieron Dunleavy, George Washington University, Washington, DC; Judy Wang, Florida Cancer Specialists and Research Institute, Sarasota, FL; and Jerome Zeldis, Sorrento Therapeutics, San Diego, CA
| | - Barry Miller
- Thomas S. Uldrick and Richard F. Little, National Cancer Institute, Bethesda; Gwynn Ison and Barry Miller, US Food and Drug Administration, Silver Spring; Michelle A. Rudek, Johns Hopkins University, Baltimore, MD; Ariela Noy, Memorial Sloan Kettering Cancer Center and Weill Medical College, New York, NY; Karl Schwartz, Patients Against Lymphoma, Riegelsville, PA; Suanna Bruinooge and Caroline Schenkel, ASCO, Alexandria, VA; Kieron Dunleavy, George Washington University, Washington, DC; Judy Wang, Florida Cancer Specialists and Research Institute, Sarasota, FL; and Jerome Zeldis, Sorrento Therapeutics, San Diego, CA
| | - Kieron Dunleavy
- Thomas S. Uldrick and Richard F. Little, National Cancer Institute, Bethesda; Gwynn Ison and Barry Miller, US Food and Drug Administration, Silver Spring; Michelle A. Rudek, Johns Hopkins University, Baltimore, MD; Ariela Noy, Memorial Sloan Kettering Cancer Center and Weill Medical College, New York, NY; Karl Schwartz, Patients Against Lymphoma, Riegelsville, PA; Suanna Bruinooge and Caroline Schenkel, ASCO, Alexandria, VA; Kieron Dunleavy, George Washington University, Washington, DC; Judy Wang, Florida Cancer Specialists and Research Institute, Sarasota, FL; and Jerome Zeldis, Sorrento Therapeutics, San Diego, CA
| | - Judy Wang
- Thomas S. Uldrick and Richard F. Little, National Cancer Institute, Bethesda; Gwynn Ison and Barry Miller, US Food and Drug Administration, Silver Spring; Michelle A. Rudek, Johns Hopkins University, Baltimore, MD; Ariela Noy, Memorial Sloan Kettering Cancer Center and Weill Medical College, New York, NY; Karl Schwartz, Patients Against Lymphoma, Riegelsville, PA; Suanna Bruinooge and Caroline Schenkel, ASCO, Alexandria, VA; Kieron Dunleavy, George Washington University, Washington, DC; Judy Wang, Florida Cancer Specialists and Research Institute, Sarasota, FL; and Jerome Zeldis, Sorrento Therapeutics, San Diego, CA
| | - Jerome Zeldis
- Thomas S. Uldrick and Richard F. Little, National Cancer Institute, Bethesda; Gwynn Ison and Barry Miller, US Food and Drug Administration, Silver Spring; Michelle A. Rudek, Johns Hopkins University, Baltimore, MD; Ariela Noy, Memorial Sloan Kettering Cancer Center and Weill Medical College, New York, NY; Karl Schwartz, Patients Against Lymphoma, Riegelsville, PA; Suanna Bruinooge and Caroline Schenkel, ASCO, Alexandria, VA; Kieron Dunleavy, George Washington University, Washington, DC; Judy Wang, Florida Cancer Specialists and Research Institute, Sarasota, FL; and Jerome Zeldis, Sorrento Therapeutics, San Diego, CA
| | - Richard F Little
- Thomas S. Uldrick and Richard F. Little, National Cancer Institute, Bethesda; Gwynn Ison and Barry Miller, US Food and Drug Administration, Silver Spring; Michelle A. Rudek, Johns Hopkins University, Baltimore, MD; Ariela Noy, Memorial Sloan Kettering Cancer Center and Weill Medical College, New York, NY; Karl Schwartz, Patients Against Lymphoma, Riegelsville, PA; Suanna Bruinooge and Caroline Schenkel, ASCO, Alexandria, VA; Kieron Dunleavy, George Washington University, Washington, DC; Judy Wang, Florida Cancer Specialists and Research Institute, Sarasota, FL; and Jerome Zeldis, Sorrento Therapeutics, San Diego, CA
| |
Collapse
|
9
|
Morey M, Ryan S, Kelly J, Liu C, Hawkins K, Schwartz K, Prvu Bettger J. THE 6TH VITAL SIGN: A MOBILE APP FOR POPULATION HEALTH SURVEILLANCE OF WALKING SPEED. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.2377] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M.C. Morey
- Medicine, VAMC and Duke Medical Centers, Durham, North Carolina,
| | - S. Ryan
- Duke University Medical Center, Durham, North Carolina
| | - J. Kelly
- Duke University Medical Center, Durham, North Carolina
| | - C. Liu
- Duke University Medical Center, Durham, North Carolina
| | - K. Hawkins
- Duke University Medical Center, Durham, North Carolina
| | - K. Schwartz
- Duke University Medical Center, Durham, North Carolina
| | | |
Collapse
|
10
|
Schweer WP, Patience JF, Schwartz K, Linhares D, Rademacher C, Allen HK, Loving CL, Ramirez A, Gabler NK. 305 A review and evaluation of antibiotic alternatives in the literature. J Anim Sci 2017. [DOI: 10.2527/asasmw.2017.305] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Helm E, Outhouse AC, Schwartz K, Dekkers JCM, Lonergan SM, Gabler NK. 330 Impact of Lawsonia intracellularis–Mycoplasma hyopneumoniae dual challenge on growth performance of pigs divergently selected for residual feed intake. J Anim Sci 2017. [DOI: 10.2527/asasmw.2017.330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Gabler NK, Curry SM, Schweer WP, Lonergan SM, Schwartz K, Burrough ER, Loving CL. 143 What are the nutritional and metabolic costs of immune system activation in pigs? J Anim Sci 2017. [DOI: 10.2527/asasmw.2017.12.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer 2016; 4:90. [PMID: 28018601 PMCID: PMC5168808 DOI: 10.1186/s40425-016-0188-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Accepted: 11/07/2016] [Indexed: 12/24/2022] Open
Abstract
Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical responses. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a hematologic malignancy Cancer Immunotherapy Guidelines panel consisting of physicians, nurses, patient advocates, and patients to develop consensus recommendations for the clinical application of immunotherapy for patients with multiple myeloma, lymphoma, and acute leukemia. These recommendations were developed following the previously established process based on the Institute of Medicine's clinical practice guidelines. In doing so, a systematic literature search was performed for high-impact studies from 2004 to 2014 and was supplemented with further literature as identified by the panel. The consensus panel met in December of 2014 with the goal to generate consensus recommendations for the clinical use of immunotherapy in patients with hematologic malignancies. During this meeting, consensus panel voting along with discussion were used to rate and review the strength of the supporting evidence from the literature search. These consensus recommendations focus on issues related to patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Overall, immunotherapy is rapidly emerging as an effective therapeutic strategy for the management of hematologic malignances. Evidence-based consensus recommendations for its clinical application are provided and will be updated as the field evolves.
Collapse
Affiliation(s)
- Michael Boyiadzis
- Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, 5150 Centre Avenue, Suite 564, Pittsburg, PA 15232 USA
| | - Michael R. Bishop
- Hematopoietic Cellular Therapy Program, University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637 USA
| | - Rafat Abonour
- Indiana University School of Medicine, 980 W. Walnut St., Walther Hall-R3, C400, Indianapolis, IN 46202 USA
| | | | | | - David Avigan
- Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215 USA
| | - Lisa Barbarotta
- Smilow Cancer Hospital at Yale New Haven, 35 Park Street, New Haven, CT 06519 USA
| | - Austin John Barrett
- National Institutes of Health, Building 10-CRC Room 3-5330, Bethesda, MD 20814 USA
| | - Koen Van Besien
- Weill Cornell Medical College, 407 E 71st St, New York, NY 10065 USA
| | | | - Ivan Borrello
- Johns Hopkins School of Medicine, 1650 Orleans St, Baltimore, MD 21231 USA
| | - Joshua Brody
- Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY 10029 USA
| | - Jill Brufsky
- University of Pittsburgh Cancer Institute, 5150 Centre Avenue, Pittsburgh, PA 15232 USA
| | - Mitchell Cairo
- New York Medical College at Maria Fareri Children’s Hospital, 100 Woods Road, Valhalla, New York 10595 USA
| | - Ajai Chari
- Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY 10029 USA
| | - Adam Cohen
- Abramson Cancer Center at the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA 19104 USA
| | - Jorge Cortes
- MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 USA
| | - Stephen J. Forman
- City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010 USA
| | - Jonathan W. Friedberg
- Wilmot Cancer Institute, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642 USA
| | - Ephraim J. Fuchs
- Johns Hopkins University School of Medicine, 401 N. Broadway, Baltimore, MD 21231 USA
| | - Steven D. Gore
- Yale Cancer Center, 333 Cedar Street, New Haven, CT 06511 USA
| | - Sundar Jagannath
- Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY 10029 USA
| | - Brad S. Kahl
- Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, MO 63110 USA
| | - Justin Kline
- The University of Chicago, 5841 S. Maryland Ave, Chicago, IL 60637 USA
| | - James N. Kochenderfer
- National Institutes of Health, National Cancer Institute, 8500 Roseweood Drive, Bethesda, MD 20814 USA
| | - Larry W. Kwak
- City of Hope National Medical Center, 1500 E. Duarte Road, Beckman Bldg., Room 4117, Duarte, CA 91010 USA
| | - Ronald Levy
- Division of Medical Oncology, Stanford University School of Medicine, 269 Campus Drive, Stanford, CA 94305 USA
| | - Marcos de Lima
- Department of Medicine-Hematology and Oncology, Case Western Reserve University, 11100 Euclid Ave., Cleveland, OH 44106 USA
| | - Mark R. Litzow
- Department of Hematology, Mayo Clinic Cancer Center, 200 First Street SW, Rochester, MN 55905 USA
| | - Anuj Mahindra
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, Box 0324, San Francisco, CA 94143 USA
| | - Jeffrey Miller
- Division of Hematology/Oncology, University of Minnesota, 420 Delaware St SE, Minneapolis, MN 55455 USA
| | - Nikhil C. Munshi
- Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana B106, Boston, MA 02215 USA
| | - Robert Z. Orlowski
- The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 429, Houston, TX 77030 USA
| | - John M. Pagel
- Swedish Cancer Institute, 1221 Madison Street, Suite 1020, Seattle, WA 98104 USA
| | - David L. Porter
- University of Pennsylvania, 3400 Civic Center Blvd, PCAM 12 South Pavilion, Philadelphia, PA 19104 USA
| | | | - Karl Schwartz
- Patients Against Lymphoma, 3774 Buckwampum Road, Riegelsville, PA 18077 USA
| | - Margaret A. Shipp
- Dana-Farber Cancer Institute, 450 Brookline Ave, Mayer 513, Boston, MA 02215 USA
| | - David Siegel
- Hackensack University Medical Center, 92 2nd St., Hackensack, NJ 07601 USA
| | - Richard M. Stone
- Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 USA
| | - Martin S. Tallman
- Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA
| | - John M. Timmerman
- University of California, Los Angeles, 10833 LeConte Ave., Los Angeles, CA 90095 USA
| | - Frits Van Rhee
- University of Arkansas for Medical Sciences, Myeloma Institute, 4301 W Markham #816, Little Rock, AR 72205 USA
| | - Edmund K. Waller
- Winship Cancer Institute, Emory University, 1365B Clifton Road NE, Atlanta, GA 30322 USA
| | - Ann Welsh
- University of Pittsburgh Medical Center, 200 Lothrop St., Pittsburgh, PA 15213 USA
| | - Michael Werner
- Patient Advocate, 33 East Bellevue Place, Chicago, IL 60611 USA
| | - Peter H. Wiernik
- Cancer Research Foundation of New York, 43 Longview Lane, Chappaqua, NY 10514 USA
| | - Madhav V. Dhodapkar
- Department of Hematology & Immunobiology, Yale University, 333 Cedar Street, Box 208021, New Haven, CT 06510 USA
| |
Collapse
|
14
|
Schweer WP, Schwartz K, Burrough ER, Yoon KJ, Sparks JC, Gabler NK. The effect of porcine reproductive and respiratory syndrome virus and porcine epidemic diarrhea virus challenge on growing pigs I: Growth performance and digestibility. J Anim Sci 2016; 94:514-22. [PMID: 27065121 PMCID: PMC7199662 DOI: 10.2527/jas.2015-9834] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Porcine reproductive and respiratory syndrome (PRRS) and porcine epidemic diarrhea (PED) are two diseases costly to the U.S. swine industry. The objective of this study was to determine the impact of PRRS virus and PED virus, alone or in combination, on growth performance, feed efficiency, and digestibility in grower pigs. Forty-two gilts (16 ± 0.98 kg BW) naïve for PRRS and PED were selected and allocated to 1 of 4 treatments. Treatments included 1) a control, 2) PRRS virus infected, 3) PED virus infected, and 4) PRRS+PED coinfection (PRP). Pigs in treatments 2 and 4 were inoculated with a live field strain of PRRS virus via intramuscular and intranasal routes at 0 d after inoculation (dpi). Treatments 3 and 4 were orally inoculated with a cloned PED virus at 15 dpi. Infection with PRRS virus was confirmed by quantitative PCR and seroconversion. Infection with PED virus was confirmed with PCR. Control pigs remained PRRS and PED virus negative throughout the study. All pigs were offered, ad libitum, a standard diet with free access to water. During the test period, PRRS reduced ADG and ADFI by 30 and 26%, respectively (P < 0.05), compared with control pigs, whereas PRP decreased ADG, ADFI, and G:F by 45, 30, and 23%, respectively (P < 0.05). Additional reductions in ADG and G:F were detected in PRP pigs compared with singular PED or PRRS treatments (33 and 16%, respectively). The impact of PED, alone or in combination, on performance (15–21 dpi) reduced ADG (0.66 vs. 0.35 vs. 0.20 kg/d; P < 0.01), ADFI (1.22 vs. 0.88 vs. 0.67 kg/d; P = 0.003), and G:F (0.54 vs. 0.39 vs. 0.31; P = 0.001) compared with control pigs. Compared with control pigs, PRRS infection did not reduce apparent total tract digestibility (ATTD) of nutrients and energy. However, PED infection, alone or in combination, decreased ATTD of DM and energy by 8 and 12%, respectively (P < 0.05). Compared with control pigs, PRP reduced N and OM ATTD by 13 and 3%, respectively (P < 0.05). No significant differences in apparent ileal digestibility (AID) were detected between virus challenges. However, Lys AID tended to be reduced in both PED treatments compared with the control (10 and 12%; P = 0.095). Altogether, PRRS reduced growth but did not alter digestibility. Pigs challenged with PED and, to a greater extent, the coinfection of PED and PRRS viruses had reduced ADG, ADFI, G:F, and ATTD of nutrients and energy.
Collapse
Affiliation(s)
- W. P. Schweer
- Department of Animal Science, Iowa State University, Ames 50011
| | - K Schwartz
- Department of Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames 50011
| | - E. R. Burrough
- Department of Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames 50011
| | - K. J. Yoon
- Department of Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames 50011
| | | | - N. K. Gabler
- Department of Animal Science, Iowa State University, Ames 50011
- Corresponding author:
| |
Collapse
|
15
|
Schweer WP, Pearce SC, Burrough ER, Schwartz K, Yoon KJ, Sparks JC, Gabler NK. The effect of porcine reproductive and respiratory syndrome virus and porcine epidemic diarrhea virus challenge on growing pigs II: Intestinal integrity and function. J Anim Sci 2016; 94:523-32. [PMID: 27065122 DOI: 10.2527/jas.2015-9836] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The objective of this study was to determine if intestinal function and integrity is altered due to porcine reproductive and respiratory syndrome (PRRS) virus and porcine epidemic diarrhea (PED) virus infection in growing pigs. Forty-two gilts (16.8 ± 0.6 kg BW), naïve for PRRS and PED, were selected and randomly assigned to 1 of 4 treatments: 1) a control (CON; = 6), 2) PRRS virus challenge only (PRRS; = 12), 3) PED virus challenge only (; = 12), or 4) coinfection of PRRS + PED viruses (PRP; = 12). Treatments 2 and 4 were inoculated with a live field strain of PRRS virus on d 0 after inoculation. Treatments 3 and 4 were inoculated with PED virus on 14 d after inoculation (dpi) and all pigs were euthanized 7 d later (21 dpi). Infection with PRRS virus was determined by viremia and seroconversion. Fecal quantitative PCR was used to confirm PED virus infection. Control pigs remained PRRS and PED virus negative throughout the study. Compared with the CON, intestinal morphology was unaffected by PRRS. As expected, PED and PRP treatments resulted in duodenum, jejunum, and ileum villus atrophy compared with the CON treatment ( < 0.01). Ex vivo transepithelial electrical resistance (TER) did not differ between CON and PRRS pigs (P < 0.05) but was reduced by 40% in PED alone ( < 0.01). Interestingly, TER was increased ( < 0.01) in the PRP pigs. Active transport of glucose was increased in PRRS pigs over CON pigs ( < 0.01), whereas PED had pigs increased ( < 0.01) active glutamine transport over the CON pigs. Jejunum GLUT2 mRNA abundance and sucrase, maltase, and Na+/K+ adenosine triphosphatase activities tended to be increased in PRRS pigs compared with CON pigs ( < 0.06). The jejunum AA transporter, SLC6A14, and mucin 2 mRNA abundance tended to be increased in PED-only pigs ( < 0.10). These data suggest that PRRS infection supports a higher affinity for glucose uptake, whereas PED favors glutamine uptake. Interestingly, digestive machinery during PED challenge remained intact. Altogether, PED but not PRRS challenges alter intestinal morphology and integrity in growing pigs.
Collapse
|
16
|
Curry SM, Gibson KA, Burrough ER, Schwartz K, Yoon KJ, Gabler NK. 254 Pigs inoculated with Porcine Epidemic Diarrhea Virus have decreased growth performance and tissue accretion compared with Controls after 42 d. J Anim Sci 2016. [DOI: 10.2527/msasas2016-254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
O'Connell AL, Schweer WP, Schwartz K, Gourley G, FitzSimmons MA, Gabler NK. 411 Increased dietary soybean meal does not affect performance during a PRRSV-Mycoplasma hyopneumoniae challenge. J Anim Sci 2016. [DOI: 10.2527/msasas2016-411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Schwartz K, Chang H, Noel M, Nikolai M, Olson K, Pernicone J, Rhee S, Kurnali P, Ord N. NT-31 * KETOGENIC DIET USED AS TREATEMENT FOR PRIMARY AGGRESSIVE BRAIN CANCERS: EXPERIENCE IN HUMANS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou265.29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Simon MS, Ruterbusch JJ, Pressler ME, Lamerato L, Krajenta R, Booza JC, Schwartz K. Abstract P5-12-03: Racial differences in breast cancer survival in a large urban integrated health system. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-12-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Despite improvements in breast cancer outcomes, there continues to be a large gap in survival between African American (AA) and White women with breast cancer, which may be due at least in part to racial differences in access to care. In order to better understand breast cancer survival disparities, we evaluated factors that predict racial differences in survival among women treated at a large integrated health care system in Southeastern Michigan. Materials and Methods: The study population included 2,387 women (34% AA) with stage I through III breast cancer treated at the Henry Ford Health System (HFHS) from 1996 through 2005. Linked datasets from the HFHS, the Metropolitan Detroit Cancer Surveillance System (MDCSS) and the U.S. Census Bureau were used to obtain socio-demographic and clinical information. Co-morbidity was assessed by the Charlson co-morbidity index (CCI), and economic deprivation was categorized into 5 quintiles of increasingly worse socioeconomic deprivation, using a census tract deprivation index (DI). Results: AA women were significantly more likely than Whites to have larger (41% vs. 32% > 2 cm) and hormone receptor (HR) negative tumors (30% vs 19%), to have a higher CCI (15% vs 9% > 2) and to reside in a more economically deprived area (46% vs. 5% residing in quintile 5). Unadjusted analysis showed that AA had a significantly higher risk of death than White women (hazards ratio [HR], 1.36, 95% confidence interval [CI], 1.16-1.59). After multivariable adjustment for clinical (age, stage, HR and CCI), and societal factors (insurance, DI), race was no longer significantly associated with overall survival, HR, 1.12, 95% CI, 0.94-1.33, p = 0.22, and 1.02, 95% CI 0.83-1.24, p = 0.88, respectively. Stratified analyses by DI showed no racial difference in survival for each of 5 levels of DI. Discussion: In a large urban integrated health care system, racial differences in breast cancer survival appear to be related to clinical and socioeconomic characteristics.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-12-03.
Collapse
Affiliation(s)
- MS Simon
- Karmanos Cancer Institute, Detroit, MI; Wayne State University, Detroit, MI; Wayne State University School of Medicine, Detroit, MI; Henry Ford Health Systems, Detroit, MI
| | - JJ Ruterbusch
- Karmanos Cancer Institute, Detroit, MI; Wayne State University, Detroit, MI; Wayne State University School of Medicine, Detroit, MI; Henry Ford Health Systems, Detroit, MI
| | - ME Pressler
- Karmanos Cancer Institute, Detroit, MI; Wayne State University, Detroit, MI; Wayne State University School of Medicine, Detroit, MI; Henry Ford Health Systems, Detroit, MI
| | - L Lamerato
- Karmanos Cancer Institute, Detroit, MI; Wayne State University, Detroit, MI; Wayne State University School of Medicine, Detroit, MI; Henry Ford Health Systems, Detroit, MI
| | - R Krajenta
- Karmanos Cancer Institute, Detroit, MI; Wayne State University, Detroit, MI; Wayne State University School of Medicine, Detroit, MI; Henry Ford Health Systems, Detroit, MI
| | - JC Booza
- Karmanos Cancer Institute, Detroit, MI; Wayne State University, Detroit, MI; Wayne State University School of Medicine, Detroit, MI; Henry Ford Health Systems, Detroit, MI
| | - K Schwartz
- Karmanos Cancer Institute, Detroit, MI; Wayne State University, Detroit, MI; Wayne State University School of Medicine, Detroit, MI; Henry Ford Health Systems, Detroit, MI
| |
Collapse
|
20
|
Ambady P, Holdhoff M, Ferrigno C, Grossman S, Anderson MD, Liu D, Conrad C, Penas-Prado M, Gilbert MR, Yung AWK, de Groot J, Aoki T, Nishikawa R, Sugiyama K, Nonoguchi N, Kawabata N, Mishima K, Adachi JI, Kurisu K, Yamasaki F, Tominaga T, Kumabe T, Ueki K, Higuchi F, Yamamoto T, Ishikawa E, Takeshima H, Yamashita S, Arita K, Hirano H, Yamada S, Matsutani M, Apok V, Mills S, Soh C, Karabatsou K, Arimappamagan A, Arya S, Majaid M, Somanna S, Santosh V, Schaff L, Armentano F, Harrison C, Lassman A, McKhann G, Iwamoto F, Armstrong T, Yuan Y, Liu D, Acquaye A, Vera-Bolanos E, Diefes K, Heathcock L, Cahill D, Gilbert M, Aldape K, Arrillaga-Romany I, Ruddy K, Greenberg S, Nayak L, Avgeropoulos N, Avgeropoulos G, Riggs G, Reilly C, Banerji N, Bruns P, Hoag M, Gilliland K, Trusheim J, Bekaert L, Borha A, Emery E, Busson A, Guillamo JS, Bell M, Harrison C, Armentano F, Lassman A, Connolly ES, Khandji A, Iwamoto F, Blakeley J, Ye X, Bergner A, Dombi E, Zalewski C, Follmer K, Halpin C, Fayad L, Jacobs M, Baldwin A, Langmead S, Whitcomb T, Jennings D, Widemann B, Plotkin S, Brandes AA, Mason W, Pichler J, Nowak AK, Gil M, Saran F, Revil C, Lutiger B, Carpentier AF, Milojkovic-Kerklaan B, Aftimos P, Altintas S, Jager A, Gladdines W, Lonnqvist F, Soetekouw P, van Linde M, Awada A, Schellens J, Brandsma D, Brenner A, Sun J, Floyd J, Hart C, Eng C, Fichtel L, Gruslova A, Lodi A, Tiziani S, Bridge CA, Baldock A, Kumthekar P, Dilfer P, Johnston SK, Jacobs J, Corwin D, Guyman L, Rockne R, Sonabend A, Cloney M, Canoll P, Swanson KR, Bromberg J, Schouten H, Schaafsma R, Baars J, Brandsma D, Lugtenburg P, van Montfort C, van den Bent M, Doorduijn J, Spalding A, LaRocca R, Haninger D, Saaraswat T, Coombs L, Rai S, Burton E, Burzynski G, Burzynski S, Janicki T, Marszalek A, Burzynski S, Janicki T, Burzynski G, Marszalek A, Cachia D, Smith T, Cardona AF, Mayor LC, Jimenez E, Hakim F, Yepes C, Bermudez S, Useche N, Asencio JL, Mejia JA, Vargas C, Otero JM, Carranza H, Ortiz LD, Cardona AF, Ortiz LD, Jimenez E, Hakim F, Yepes C, Useche N, Bermudez S, Asencio JL, Carranza H, Vargas C, Otero JM, Bartels C, Quintero A, Restrepo CE, Gomez S, Bernal-Vaca L, Lema M, Cardona AF, Ortiz LD, Useche N, Bermudez S, Jimenez E, Hakim F, Yepes C, Mejia JA, Bernal-Vaca L, Restrepo CE, Gomez S, Quintero A, Bartels C, Carranza H, Vargas C, Otero JM, Carlo M, Omuro A, Grommes C, Kris M, Nolan C, Pentsova E, Pietanza M, Kaley T, Carrabba G, Giammattei L, Draghi R, Conte V, Martinelli I, Caroli M, Bertani G, Locatelli M, Rampini P, Artoni A, Carrabba G, Bertani G, Cogiamanian F, Ardolino G, Zarino B, Locatelli M, Caroli M, Rampini P, Chamberlain M, Raizer J, Soffetti R, Ruda R, Brandsma D, Boogerd W, Taillibert S, Le Rhun E, Jaeckle K, van den Bent M, Wen P, Chamberlain M, Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Kerloeguen Y, Guijarro A, Cloughsey T, Choi JH, Hong YK, Conrad C, Yung WKA, deGroot J, Gilbert M, Loghin M, Penas-Prado M, Tremont I, Silberman S, Picker D, Costa R, Lycette J, Gancher S, Cullen J, Winer E, Hochberg F, Sachs G, Jeyapalan S, Dahiya S, Stevens G, Peereboom D, Ahluwalia M, Daras M, Hsu M, Kaley T, Panageas K, Curry R, Avila E, Fuente MDL, Omuro A, DeAngelis L, Desjardins A, Sampson J, Peters K, Ranjan T, Vlahovic G, Threatt S, Herndon J, Boulton S, Lally-Goss D, McSherry F, Friedman A, Friedman H, Bigner D, Gromeier M, Prust M, Kalpathy-Cramer J, Poloskova P, Jafari-Khouzani K, Gerstner E, Dietrich J, Fabi A, Villani V, Vaccaro V, Vidiri A, Giannarelli D, Piludu F, Anelli V, Carapella C, Cognetti F, Pace A, Flowers A, Flowers A, Killory B, Furuse M, Miyatake SI, Kawabata S, Kuroiwa T, Garciarena P, Anderson MD, Hamilton J, Schellingerhout D, Fuller GN, Sawaya R, Gilbert MR, Gilbert M, Pugh S, Won M, Blumenthal D, Vogelbaum M, Aldape K, Colman H, Chakravarti A, Jeraj R, Dignam J, Armstrong T, Wefel J, Brown P, Jaeckle K, Schiff D, Brachman D, Werner-Wasik M, Tremont-Lukats I, Sulman E, Mehta M, Gill B, Yun J, Goldstein H, Malone H, Pisapia D, Sonabend AM, Mckhann GK, Sisti MB, Sims P, Canoll P, Bruce JN, Girvan A, Carter G, Li L, Kaltenboeck A, Chawla A, Ivanova J, Koh M, Stevens J, Lahn M, Gore M, Hariharan S, Porta C, Bjarnason G, Bracarda S, Hawkins R, Oudard S, Zhang K, Fly K, Matczak E, Szczylik C, Grossman R, Ram Z, Hamza M, O'Brien B, Mandel J, DeGroot J, Han S, Molinaro A, Berger M, Prados M, Chang S, Clarke J, Butowski N, Hashimoto N, Chiba Y, Tsuboi A, Kinoshita M, Hirayama R, Kagawa N, Oka Y, Oji Y, Sugiyama H, Yoshimine T, Hawkins-Daarud A, Jackson PR, Swanson KR, Sarmiento JM, Ly D, Jutla J, Ortega A, Carico C, Dickinson H, Phuphanich S, Rudnick J, Patil C, Hu J, Iglseder S, Nowosielski M, Nevinny-Stickel M, Stockhammer G, Jain R, Poisson L, Scarpace L, Mikkelsen T, Kirby J, Freymann J, Hwang S, Gutman D, Jaffe C, Brat D, Flanders A, Janicki T, Burzynski S, Burzynski G, Marszalek A, Jiang C, Wang H, Jo J, Williams B, Smolkin M, Wintermark M, Shaffrey M, Schiff D, Juratli T, Soucek S, Kirsch M, Schackert G, Kakkar A, Kumar S, Bhagat U, Kumar A, Suri A, Singh M, Sharma M, Sarkar C, Suri V, Kaley T, Barani I, Chamberlain M, McDermott M, Raizer J, Rogers L, Schiff D, Vogelbaum M, Weber D, Wen P, Kalita O, Vaverka M, Hrabalek L, Zlevorova M, Trojanec R, Hajduch M, Kneblova M, Ehrmann J, Kanner AA, Wong ET, Villano JL, Ram Z, Khatua S, Fuller G, Dasgupta S, Rytting M, Vats T, Zaky W, Khatua S, Sandberg D, Foresman L, Zaky W, Kieran M, Geoerger B, Casanova M, Chisholm J, Aerts I, Bouffet E, Brandes AA, Leary SES, Sullivan M, Bailey S, Cohen K, Mason W, Kalambakas S, Deshpande P, Tai F, Hurh E, McDonald TJ, Kieran M, Hargrave D, Wen PY, Goldman S, Amakye D, Patton M, Tai F, Moreno L, Kim CY, Kim T, Han JH, Kim YJ, Kim IA, Yun CH, Jung HW, Koekkoek JAF, Reijneveld JC, Dirven L, Postma TJ, Vos MJ, Heimans JJ, Taphoorn MJB, Koeppen S, Hense J, Kong XT, Davidson T, Lai A, Cloughesy T, Nghiemphu PL, Kong DS, Choi YL, Seol HJ, Lee JI, Nam DH, Kool M, Jones DTW, Jager N, Northcott PA, Pugh T, Hovestadt V, Markant S, Esparza LA, Bourdeaut F, Remke M, Taylor MD, Cho YJ, Pomeroy SL, Schuller U, Korshunov A, Eils R, Wechsler-Reya RJ, Lichter P, Pfister SM, Krel R, Krutoshinskaya Y, Rosiello A, Seidman R, Kowalska A, Kudo T, Hata Y, Maehara T, Kumthekar P, Bridge C, Patel V, Rademaker A, Helenowski I, Mrugala M, Rockhill J, Swanson K, Grimm S, Raizer J, Meletath S, Bennett M, Nestor VA, Fink KL, Lee E, Reardon D, Schiff D, Drappatz J, Muzikansky A, Hammond S, Grimm S, Norden A, Beroukhim R, McCluskey C, Chi A, Batchelor T, Smith K, Gaffey S, Gerard M, Snodgras S, Raizer J, Wen P, Leeper H, Johnson D, Lima J, Porensky E, Cavaliere R, Lin A, Liu J, Evans J, Leuthardt E, Dacey R, Dowling J, Kim A, Zipfel G, Grubb R, Huang J, Robinson C, Simpson J, Linette G, Chicoine M, Tran D, Liubinas SV, D'Abaco GM, Moffat B, Gonzales M, Feleppa F, Nowell CJ, Gorelick A, Drummond KJ, Morokoff AP, O'Brien TJ, Kaye AH, Loghin M, Melhem-Bertrandt A, Penas-Prado M, Zaidi T, Katz R, Lupica K, Stevens G, Ly I, Hamilton S, Rostomily R, Rockhill J, Mrugala M, Mandel J, Yust-Katz S, de Groot J, Yung A, Gilbert M, Burzynski S, Janicki T, Burzynski G, Marszalek A, Pachow D, Kliese N, Kirches E, Mawrin C, McNamara MG, Lwin Z, Jiang H, Chung C, Millar BA, Sahgal A, Laperriere N, Mason WP, Megyesi J, Salehi F, Merker V, Slusarz K, Muzikansky A, Francis S, Plotkin S, Mishima K, Adachi JI, Suzuki T, Uchida E, Yanagawa T, Watanabe Y, Fukuoka K, Yanagisawa T, Wakiya K, Fujimaki T, Nishikawa R, Moiyadi A, Kannan S, Sridhar E, Gupta T, Shetty P, Jalali R, Alshami J, Lecavalier-Barsoum M, Guiot MC, Tampieri D, Kavan P, Muanza T, Nagane M, Kobayashi K, Takayama N, Shiokawa Y, Nakamura H, Makino K, Hideo T, Kuroda JI, Shinojima N, Yano S, Kuratsu JI, Nambudiri N, Arrilaga I, Dunn I, Folkerth R, Chi S, Reardon D, Nayak L, Omuro A, DeAngelis L, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas J, Reimers HJ, Peereboom D, Rosenfeld S, Garst J, Ramnath N, Wing P, Zheng M, Urban P, Abrey L, Wen P, Nayak L, DeAngelis LM, Wen PY, Brandes AA, Soffietti R, Peereboom DM, Lin NU, Chamberlain M, Macdonald D, Galanis E, Perry J, Jaeckle K, Mehta M, Stupp R, van den Bent M, Reardon DA, Norden A, Hammond S, Drappatz J, Phuphanich S, Reardon D, Wong E, Plotkin S, Lesser G, Raizer J, Batchelor T, Lee E, Kaley T, Muzikansky A, Doherty L, LaFrankie D, Ruland S, Smith K, Gerard M, McCluskey C, Wen P, Norden A, Schiff D, Ahluwalia M, Lesser G, Nayak L, Lee E, Muzikansky A, Dietrich J, Smith K, Gaffey S, McCluskey C, Ligon K, Reardon D, Wen P, Bush NAO, Kesari S, Scott B, Ohno M, Narita Y, Miyakita Y, Arita H, Matsushita Y, Yoshida A, Fukushima S, Ichimura K, Shibui S, Okamura T, Kaneko S, Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Maire JP, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Barrie M, del Rio MS, Gonzalez-Aguilar A, Houllier C, Tanguy ML, Hoang-Xuan K, Omuro A, Abrey L, Raizer J, Paleologos N, Forsyth P, DeAngelis L, Kaley T, Louis D, Cairncross JG, Matasar M, Mehta J, Grimm S, Moskowitz C, Sauter C, Opinaldo P, Torcuator R, Ortiz LD, Cardona AF, Hakim F, Jimenez E, Yepes C, Useche N, Bermudez S, Mejia JA, Asencio JL, Carranza H, Vargas C, Otero JM, Lema M, Pace A, Villani V, Fabi A, Carapella CM, Patel A, Allen J, Dicker D, Sheehan J, El-Deiry W, Glantz M, Tsyvkin E, Rauschkolb P, Pentsova E, Lee M, Perez A, Norton J, Uschmann H, Chamczuck A, Khan M, Fratkin J, Rahman R, Hempfling K, Norden A, Reardon DA, Nayak L, Rinne M, Doherty L, Ruland S, Rai A, Rifenburg J, LaFrankie D, Wen P, Lee E, Ranjan T, Peters K, Vlahovic G, Friedman H, Desjardins A, Reveles I, Brenner A, Ruda R, Bello L, Castellano A, Bertero L, Bosa C, Trevisan E, Riva M, Donativi M, Falini A, Soffietti R, Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Nishikawa R, Dahr S, Hilton M, Garcia J, Cloughesy T, Sasaki H, Nishiyama Y, Yoshida K, Hirose Y, Schwartz M, Grimm S, Kumthekar P, Fralin S, Rice L, Drawz A, Helenowski I, Rademaker A, Raizer J, Schwartz K, Chang H, Nikolai M, Kurniali P, Olson K, Pernicone J, Sweeley C, Noel M, Sharma M, Gupta R, Suri V, Singh M, Sarkar C, Shibahara I, Sonoda Y, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Suzuki H, Watanabe T, Ishioka C, Tominaga T, Shih K, Chowdhary S, Rosenblatt P, Weir AB, Shepard G, Williams JT, Shastry M, Hainsworth JD, Singer S, Riely GJ, Kris MG, Grommes C, Sanders MWCB, Arik Y, Seute T, Robe PAJT, Leijten FSS, Snijders TJ, Sturla L, Culhane JJ, Donahue J, Jeyapalan S, Suchorska B, Jansen N, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A, Niyazi M, Bartenstein P, Schnell O, Kreth FW, LaFougere C, Tonn JC, Taillandier L, Wittwer B, Blonski M, Faure G, De Carvalho M, Le Rhun E, Tanaka K, Sasayama T, Nishihara M, Mizukawa K, Kohmura E, Taylor S, Newell K, Graves L, Timmer M, Cramer C, Rohn G, Goldbrunner R, Turner S, Gergel T, Lacroix M, Toms S, Ueki K, Higuchi F, Sakamoto S, Kim P, Salgado MAV, Rueda AG, Urzaiz LL, Villanueva MG, Millan JMS, Cervantes ER, Pampliega RA, de Pedro MDA, Berrocal VR, Mena AC, van Zanten SV, Jansen M, van Vuurden D, Huisman M, Hoekstra O, van Dongen G, Kaspers GJ, Schlamann A, von Bueren AO, Hagel C, Kramm C, Kortmann RD, Muller K, Friedrich C, Muller K, von Hoff K, Kwiecien R, Pietsch T, Warmuth-Metz M, Gerber NU, Hau P, Kuehl J, Kortmann RD, von Bueren AO, Rutkowski S, von Bueren AO, Friedrich C, von Hoff K, Kwiecien R, Muller K, Pietsch T, Warmuth-Metz M, Kuehl J, Kortmann RD, Rutkowski S, Walker J, Tremont I, Armstrong T, Wang H, Jiang C, Wang H, Jiang C, Warren P, Robert S, Lahti A, White D, Reid M, Nabors L, Sontheimer H, Wen P, Yung A, Mellinghoff I, Lamborn K, Ramkissoon S, Cloughesy T, Rinne M, Omuro A, DeAngelis L, Gilbert M, Chi A, Batchelor T, Colman H, Chang S, Nayak L, Massacesi C, DiTomaso E, Prados M, Reardon D, Ligon K, Wong ET, Elzinga G, Chung A, Barron L, Bloom J, Swanson KD, Elzinga G, Chung A, Wong ET, Wu W, Galanis E, Wen P, Das A, Fine H, Cloughesy T, Sargent D, Yoon WS, Yang SH, Chung DS, Jeun SS, Hong YK, Yust-Katz S, Milbourne A, Diane L, Gilbert M, Armstrong T, Zaky W, Weinberg J, Fuller G, Ketonen L, McAleer MF, Ahmed N, Khatua S, Zaky W, Olar A, Stewart J, Sandberg D, Foresman L, Ketonen L, Khatua S. NEURO/MEDICAL ONCOLOGY. Neuro Oncol 2013; 15:iii98-iii135. [PMCID: PMC3823897 DOI: 10.1093/neuonc/not182] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/14/2023] Open
|
21
|
Walker R, Schwartz K. Utilizing Everyday Technology to Increase Workplace Efficiency. J Acad Nutr Diet 2013. [DOI: 10.1016/j.jand.2013.06.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
22
|
|
23
|
Schwartz K, Mercadier JJ, Lompré AM. Génétique moléculaire de l'hypertrophie cardiaque. Med Sci (Paris) 2013. [DOI: 10.4267/10608/3440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
24
|
Noch E, Pina-Oviedo S, Perez-Liz G, Bookland M, Del Valle L, Gordon J, Khalili K, Juratli TA, Peitzsch M, Geiger K, Schackert G, Eisenhofer G, Krex D, Chaumeil MM, Woods SM, Danforth RM, Yoshihara H, Lodi A, Robinson A, Lupo JM, Pieper RO, Phillips JJ, Ronen SM, Schonberg DL, Heddleston JM, Hjelmeland AB, Rich JN, Rahim SAA, Sanzey M, Bjerkvig R, Niclou SP, Mustafa DAM, Swagemakers SMA, van der Spek PJ, Kros JM, Vartanian A, Singh SK, Zadeh G, Lim KS, Lim KJ, Orr BA, Price AC, Eberhart CG, Bar EE, Liu WM, Huang P, Nowacki A, Distelhorst C, Lathia J, Rich J, Kappes J, Gladson C, Schwartz K, Chang H, Karl Olson L. LAB-METABOLIC PATHWAYS. Neuro Oncol 2012. [DOI: 10.1093/neuonc/nos226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Smith BF, Colburn DS, Schubert G, Schwartz K, Sonett CP. Induced magnetosphere of the Moon: 2. Experimental results from Apollo 12 and Explorer 35. ACTA ACUST UNITED AC 2012. [DOI: 10.1029/ja078i025p05437] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
26
|
|
27
|
|
28
|
Peterson L, Soliman A, Ruterbusch JJ, Smith N, Schwartz K. Comparison of exposures among Arab American and non-Hispanic White female thyroid cancer cases in metropolitan Detroit. J Immigr Minor Health 2012; 13:1033-40. [PMID: 21647624 DOI: 10.1007/s10903-011-9485-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Arab American (ArA) women may be at greater risk for thyroid cancer (TC) than White women. This case-case comparison explored differences in known and proposed risk factors of TC among ArA and non-Hispanic White (NHW) female TC cases in metropolitan Detroit. Cases of invasive TC identified from a population-based registry responded to a telephone survey regarding potential TC risk factors. Thirty ArA women (response rate 52%) and 70 NHW women (67%) participated. NHW women reported significantly more prior thyroid disease (TD), family history of TD, hormone use, cumulative years of hormone use, cigarette and alcohol consumption. In adjusted logistic regression analysis, ArA women had significantly higher odds of exposure to dental x-rays (OR = 3.48, CI 1.01-12.00) and medical radiation (OR = 13.58, CI 1.49-124.04) than NHW women. Risk factors for TC may differ among ArA women and their NHW counterparts.
Collapse
Affiliation(s)
- L Peterson
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | | | | | | | | |
Collapse
|
29
|
Hofmann M, Große-Hovest L, Nübling T, Pyż E, Bamberg ML, Aulwurm S, Bühring HJ, Schwartz K, Haen SP, Schilbach K, Rammensee HG, Salih HR, Jung G. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia. Leukemia 2012; 26:1228-37. [PMID: 22289926 DOI: 10.1038/leu.2011.372] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The therapeutic efficacy of humanized or chimeric second-generation antitumor antibodies is clearly established, but often limited. In recent years, defined modifications of the glycosylation pattern or the amino-acid sequence of the human immunoglobulin G1 Fc part have resulted in the development of third-generation antibodies with improved capability to recruit Fc receptor-bearing effector cells. The first antibodies of this kind, currently evaluated in early clinical trials, are directed against lymphoma-associated antigens. Fc-engineered antibodies targeting myeloid leukemia are not yet available. We here report on the generation and preclinical characterization of an Fc-optimized antibody directed to the FMS-related tyrosine kinase 3 (FLT3), an antigen expressed on the leukemic blasts of all investigated patients with acute myeloid leukemia (AML). This antibody, termed 4G8SDIEM, mediated markedly enhanced cellular cytotoxicity against FLT3-expressing cell lines as well as blasts of AML patients. FLT3 expression levels on AML cells varied between 300 and 4600 molecules/cell and, in most cases, were substantially higher than those detected on normal hematopoietic precursor cells and dendritic cells (approximately 300 molecules/cell). Antibody-mediated cytotoxicity against these normal cells was not detectable. 4G8SDIEM has been produced in pharmaceutical quality in a university-owned production unit and is currently used for the treatment of leukemia patients.
Collapse
Affiliation(s)
- M Hofmann
- Department of Immunology, Eberhard-Karls University, Tübingen, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Simon MS, Lamerato L, Krajenta R, Booza J, Ruterbusch J, Kunz S, Schwartz K. P2-14-05: Racial Differences in the Use of Adjuvant Chemotherapy for Breast Cancer in a Large Urban Integrated Health System. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-14-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Despite improvements in breast cancer treatment, there continues to be a gap in survival between African American (AA) and White women with breast cancer, which may be due at least in part to racial differences in the patterns of care. In order to better understand breast cancer survival disparities, we evaluated racial differences in the receipt of adjuvant chemotherapy among women treated at a large integrated health care system in Southeastern Michigan. Materials and Methods: The study population included 2,234 women (33 % AA) with stage I through III breast cancer treated at the Henry Ford Health System (HFHS) from 1996 through 2005. Linked datasets from the HFHS, the Metropolitan Detroit Cancer Surveillance System (MDCSS) and the U.S. Census Bureau were used to obtain sociodemographic and clinical information. Co-morbidity was assessed by the Charlson co-morbidity index (CCI), and economic deprivation was categorized using a neighborhood deprivation index (DI). Results: AA women were significantly more likely than Whites to have larger tumors (40% vs. 31% > 2 cm), as well as more aggressive tumors (29% vs 19% estrogen and progesterone negative). AA women were also significantly more likely than Whites to have other co-morbid conditions (15 % vs. 8% with a CCI of 2+) and to reside in a more economically deprived area (45% vs. 5% reside in the most deprived area). While AA women were more likely to receive adjuvant chemotherapy (47% vs. 43%, p=0.0278), they were also more likely to have a delay in initiation of treatment (57% vs 45% delayed beyond 60 days from diagnosis, p=0.0004). After multivariable adjustment for age, DI, CCI, insurance and surgery, there were no racial differences in treatment delay (Odds Ratio 1.20, 95% confidence interval, 0.82−1.77). Discussion: In a large urban integrated health care system, racial differences in the delay in receipt of adjuvant chemotherapy for breast cancer can be explained by clinical and socioeconomic characteristics.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-14-05.
Collapse
Affiliation(s)
- MS Simon
- 1Karmanos Cancer Institute at Wayne State University, Detroit, MI; Henry Ford Health System, Detroit, MI; Wayne State University, Detroit, MI
| | - L Lamerato
- 1Karmanos Cancer Institute at Wayne State University, Detroit, MI; Henry Ford Health System, Detroit, MI; Wayne State University, Detroit, MI
| | - R Krajenta
- 1Karmanos Cancer Institute at Wayne State University, Detroit, MI; Henry Ford Health System, Detroit, MI; Wayne State University, Detroit, MI
| | - J Booza
- 1Karmanos Cancer Institute at Wayne State University, Detroit, MI; Henry Ford Health System, Detroit, MI; Wayne State University, Detroit, MI
| | - J Ruterbusch
- 1Karmanos Cancer Institute at Wayne State University, Detroit, MI; Henry Ford Health System, Detroit, MI; Wayne State University, Detroit, MI
| | - S Kunz
- 1Karmanos Cancer Institute at Wayne State University, Detroit, MI; Henry Ford Health System, Detroit, MI; Wayne State University, Detroit, MI
| | - K Schwartz
- 1Karmanos Cancer Institute at Wayne State University, Detroit, MI; Henry Ford Health System, Detroit, MI; Wayne State University, Detroit, MI
| |
Collapse
|
31
|
Hofmann JN, Baccarelli A, Schwartz K, Davis FG, Ruterbusch JJ, Hoxha M, McCarthy BJ, Savage SA, Wacholder S, Rothman N, Graubard BI, Colt JS, Chow WH, Purdue MP. Risk of renal cell carcinoma in relation to blood telomere length in a population-based case-control study. Br J Cancer 2011; 105:1772-5. [PMID: 22033273 PMCID: PMC3242602 DOI: 10.1038/bjc.2011.444] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Background: There are few known risk factors for renal cell carcinoma (RCC). Two small hospital-based case–control studies suggested an association between short blood telomere length (TL) and increased RCC risk. Methods: We conducted a large population-based case–control study in two metropolitan regions of the United States comparing relative TL in DNA derived from peripheral blood samples from 891 RCC cases and 894 controls. Odds ratios and 95% confidence intervals were estimated using unconditional logistic regression in both unadjusted and adjusted models. Results: Median TL was 0.85 for both cases and controls (P=0.40), and no differences in RCC risk by quartiles of TL were observed. Results of analyses stratified by age, sex, race, tumour stage, and time from RCC diagnosis to blood collection were similarly null. In multivariate analyses among controls, increasing age and history of hypertension were associated with shorter TL (P<0.001 and P=0.07, respectively), and African Americans had longer TL than Caucasians (P<0.001). Conclusion: These data do not support the hypothesis that blood TL is associated with RCC. This population-based case–control study is, to our knowledge, the largest investigation to date of TL and RCC.
Collapse
Affiliation(s)
- J N Hofmann
- Division of Cancer Epidemiology and Genetics, Occupational and Environmental Epidemiology Branch, National Cancer Institute, 6120 Executive Boulevard, Bethesda, MD 20892-7240, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Isunju JB, Schwartz K, Schouten MA, Johnson WP, van Dijk MP. Socio-economic aspects of improved sanitation in slums: a review. Public Health 2011; 125:368-76. [PMID: 21616514 DOI: 10.1016/j.puhe.2011.03.008] [Citation(s) in RCA: 114] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2010] [Revised: 01/22/2011] [Accepted: 03/17/2011] [Indexed: 11/25/2022]
Abstract
This socio-economic review provides an overview of the sanitation crisis in slum areas, and re-emphasizes the importance of sanitation. It highlights a lack of recognition of actual drivers for sanitation improvements, and the complexities in the provision of sanitation services in the context of urban slums with a mix of tenants and landlords. It elaborates how the drivers of demand for sanitation outlined in contemporary research are not universal but are rather context specific. The authors point out specific knowledge gaps for future research; for example, the need to establish a scientific basis for context-specific drivers of demand for sanitation improvements in slums, and a better understanding of associated complexities in order to set boundary conditions for achieving desired improvements.
Collapse
Affiliation(s)
- J B Isunju
- Department of Disease Control and Environmental Health, Makerere University School of Public Health, Kampala, Uganda.
| | | | | | | | | |
Collapse
|
33
|
Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L. Stroke in relation to use of raloxifene and other drugs against osteoporosis. Osteoporos Int 2011; 22:1037-45. [PMID: 20449570 DOI: 10.1007/s00198-010-1276-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/10/2010] [Accepted: 04/08/2010] [Indexed: 10/19/2022]
Abstract
UNLABELLED Prior studies have associated fatal stroke with raloxifene. In a cohort study, we found no excess risk of stroke with raloxifene; whereas, an excess risk of stroke and fatal stroke was seen with alendronate and etidronate. However, the excess risks were small. PURPOSE We aim to study the association between use of raloxifene and other drugs against osteoporosis and risk of stroke. METHODS This is a nationwide cohort study from Denmark. All users of bisphosphonates and other drugs against osteoporosis between 1996 and 2006 (n = 103,562) as exposed group and three age- and gender-matched controls from the general population (n = 310,683). RESULTS Before the drugs were started, patients later initiating alendronate or raloxifene had fewer strokes than the controls. In contrast, patients who later did start clodronate have more strokes. Among the later users of other bisphosphonates, strontium ranelate or parathyroid hormone, no change in the risk of stroke was present. Patients who started raloxifene neither had an excess risk of strokes nor of fatal strokes. No dose-response relationship was present. Among users of alendronate, a decreasing overall risk of stroke was seen with increasing dose. However, for fatal strokes, the risk increased with increasing dose of alendronate. Among users of etidronate, no trend with dose was present for overall stroke risk; whereas for fatal strokes, an increasing risk was seen with increasing dose of etidronate. CONCLUSIONS Raloxifene does not seem associated with an excess risk of strokes. The increase seen for alendronate did not seem to be causal as no classical dose-response relationship was present. The dose-response relationship for fatal strokes with alendronate and etidronate needs further examination. However, the excess risks were small and may be due to the underlying disease.
Collapse
Affiliation(s)
- P Vestergaard
- Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Tage Hansens Gade 2, DK-8000 Arhus C, Denmark.
| | | | | | | | | |
Collapse
|
34
|
Trautmann C, Costantini JM, Meftah A, Schwartz K, Stoquert JP, Toulemonde M. Swelling of SiO2 Quartz Induced by Energetic Heavy Ions. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-504-123] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTA pronounced swelling effect occurs when irradiating SiO2 quartz with heavy ions (F, S, Cu, Kr, Xe, Ta, and Pb) in the electronic energy loss regime. Using a profilometer, the out-of-plane swelling was measured by scanning over the border line between an irradiated and a virgin area of the sample surface. The step height varied between 20 and 300 nm depending on the fluence, the electronic energy loss and the total range of the ions. From complementary Rutherford backscattering experiments under channelling condition (RBS-C), the damage fraction and corresponding track radii were extracted. Normalising the step height per incoming ion and by the projected range, a critical energy loss of 1.8 ± 0.5 keV/nm was found which is in good agreement with the threshold observed by RBS-C. Swelling can be explained by the amorphisation induced along the ion trajectories. The experimental results in quartz are compared to swelling data obtained under similar irradiation conditions in LiNbO3
Collapse
|
35
|
Lompre AM, Mercadier JJ, Wisnewsky C, Bouveret P, Pantaloni C, D'Albis A, Schwartz K. Species- and age-dependent changes in the relative amounts of cardiac myosin isoenzymes in mammals. Dev Biol 2010; 84:286-90. [PMID: 20737866 DOI: 10.1016/0012-1606(81)90396-1] [Citation(s) in RCA: 237] [Impact Index Per Article: 16.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
In mice, rabbits, and pigs, two basic types of cardiac myosin isoenzymes were found by electrophoresis of native molecules: a fast-migrating form with high Ca(2+)-dependent ATPase activity and a slow-migrating form with low activity. According to the nomenclature of J. F. Y. Hoh, P. A. McGrath, and P. T. Hale (1978, J. Mol. Cell. Cardiol. 10, 1053-1076) these forms are called, respectively, V1 and V3. In all species, myosin was essentially V3 during fetal life, while V1 appeared around the time of birth. There were species differences in adults: mice remained V1, while rabbits and pigs returned to V3 after 3 weeks of age. Adult dog, beef, and human myosins were also composed of the V3 form only.
Collapse
Affiliation(s)
- A M Lompre
- U 127 INSERM Hopital Lariboisière, 41 Bd de La Chapelle, 75010 Paris, France
| | | | | | | | | | | | | |
Collapse
|
36
|
Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L. Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism. Osteoporos Int 2010; 21:1591-7. [PMID: 19859641 DOI: 10.1007/s00198-009-1091-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2009] [Accepted: 10/02/2009] [Indexed: 10/20/2022]
Abstract
SUMMARY Prior studies have associated raloxifene and strontium ranelate with deep venous thromboembolism and pulmonary embolism. In a cohort study, we observed an increased risk also with the bisphosphonates. However, the increase was present already before the start of bisphosphonates pointing at an effect of the underlying condition. INTRODUCTION We seek to study the association between use of drugs against osteoporosis and risk of deep venous thromboembolism (DVT) and pulmonary embolism (PE). METHODS Nationwide register-based cohort study from Denmark with all users of bisphosphonates and other drugs against osteoporosis between 1996 and 2006 (n = 103,562) as cases and three age- and gender-matched controls from the general population (n = 310,683). RESULTS Before start of a drug against osteoporosis, an increased risk of DVT/PE was present in the crude analysis for alendronate, etidronate, and risedronate. However, upon adjustment, this increase in risk disappeared. Before start of raloxifene, a decreased risk of DVT/PE was present (odds ratio (OR) = 0.53, 95% confidence interval (CI), 0.39-0.71). After start of a drug, alendronate (HR = 1.20, 95% CI, 1.00-1.43), clodronate (HR = 4.06, 95% CI, 1.47-11.2), and etidronate (HR = 1-37, 95% CI, 1.23-1.51) were all associated with an increased risk of DVT/PE, while raloxifene was only borderline, significantly associated with risk of DVT/PE (HR = 1.64, 95% CI, 0.97-2.77). No dose-response relationship was present except for alendronate, where the risk was inversely associated with dose, i.e., the risk of DVT/PE decreased with increasing average daily dose. The HR for DVT/PE was higher with clodronate and etidronate than with alendronate. Alendronate and raloxifene carried the same risk for DVT/PE. CONCLUSION Bisphosphonates seem associated with an increased risk of DVT/PE. However, the association does not seem to be causal.
Collapse
Affiliation(s)
- P Vestergaard
- Department of Endocrinology and Metabolism C, Aarhus University Hospital, Tage Hansens Gade 2, 8000 Arhus C, Denmark.
| | | | | | | | | |
Collapse
|
37
|
Stork H, Dinse KP, Ditter M, Fujara F, Masierak W, Neumann R, Schuster B, Schwartz K, Trautmann C. Spatially resolved nuclear spin relaxation, electron spin relaxation and light absorption in swift heavy ion irradiated LiF crystals. J Phys Condens Matter 2010; 22:185402. [PMID: 21393683 DOI: 10.1088/0953-8984/22/18/185402] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Spatially resolved (19)F and (7)Li spin-lattice relaxation rates are measured for LiF single crystals after irradiation with two kinds of swift heavy ions ((12)C of 133 MeV and (208)Pb of 1.78 GeV incident energy). Like in earlier studies on (130)Xe and (238)U irradiated LiF crystals, we found a strong enhancement of the nuclear spin-lattice relaxation rate within the ion penetration depth and a slight--but still significant--enhancement beyond. By evaluating the nuclear relaxation rate enhancement within the ion range after irradiation with different projectiles, a universal relationship between the spin-lattice relaxation rate and the dose is deduced. The results of accompanying X-band electron paramagnetic resonance relaxation measurements and optical absorption spectroscopy are included in a physical interpretation of this relationship. Also the reason for the enhanced relaxation rate beyond the ion range is further discussed.
Collapse
Affiliation(s)
- H Stork
- Institut für Festkörperphysik, TU Darmstadt, Hochschulstraße 6, 64289 Darmstadt, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Schwartz K. Interest, attitudes, and participation in clinical trials among lymphoma patients with online access. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19514 Background: There is an increasing number of investigational agents for lymphomas and a limited patient pool, approximately 5% of available patients. Thus, identifying and addressing obstacles to study enrollment is vital to making progress. Methods: This analysis was made from a non-random population of 251 lymphoma patients with online access to our survey. Results: In this cohort, 43% reported High Interest in clinical trials, 50% have Considered Trials, and 27% Have Participated. Patients who considered studies (126) ranked the following reasons for declining as significant: Randomization (70), Insurance (49), Study Risks / Toxicities (42), Travel and Lodging (30), Eligibility (28), Tests and Procedures (12), and a perception that Regular Treatment is superior (6). See Table 1 for associations with consideration of clinical trials and participation. Conclusions: In this cohort, interest in clinical trials and participation rates were much higher than generally cited. As expected, the discussion of clinical trials with the patient's oncologist was associated with the highest consideration (85%) and participation (53%) rates, suggesting a need to increase awareness of study protocols among treating physicians so that this discussion can become more routine. Patient issues and perceptions regarding randomization, study risk, eligibility, and tests and procedures suggest an opportunity to improve enrollment in clinical trials by focusing on these aspects of study design, specifically, attending to the rationale of the protocol as a treatment decision. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Schwartz
- Patients Against Lymphoma, Riegelsville, PA; Advisors to Patients Against Lymphoma
| | | |
Collapse
|
39
|
Friedrich FW, Bausero P, Sun Y, Treszl A, Kramer E, Juhr D, Richard P, Wegscheider K, Schwartz K, Brito D, Arbustini E, Waldenstrom A, Isnard R, Komajda M, Eschenhagen T, Carrier L. A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy. Eur Heart J 2009; 30:1648-55. [DOI: 10.1093/eurheartj/ehp153] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
|
40
|
Stork H, Dinse KP, Fujara F, Hamburger A, Jakes P, Neumann R, Schuster B, Schwartz K, Trautmann C. Spatially resolved characterization of Xe ion irradiated LiF crystals using static field gradient NMR. J Phys Condens Matter 2008; 20:465215. [PMID: 21693854 DOI: 10.1088/0953-8984/20/46/465215] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Spatially resolved (19)F and (7)Li nuclear magnetic resonance (NMR) spin-lattice relaxation rates have been measured in LiF crystals irradiated with 1.44 GeV Xe ions at fluences from 10(10) to 10(12) ions cm(-2). In addition, the F-centre concentration has been measured by optical absorption spectroscopy and the concentration of paramagnetic centres by electron paramagnetic resonance (EPR). Within the ion range, the relaxation rate turns out to increase linearly with the concentration of paramagnetic centres but super-linearly with the F-centre concentration. Beyond the ion range, the relaxation rate is still significantly enhanced compared to non-irradiated LiF.
Collapse
Affiliation(s)
- H Stork
- Institut für Festkörperphysik, TU Darmstadt, Hochschulstraße 6, 64289 Darmstadt, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
BACKGROUND In this meta-analysis, we investigated whether response inhibition is sensitive to attention deficit hyperactivity disorder (ADHD) status and, if so, what influence maturation has on this attentional symptom of ADHD. METHOD We examined 25 studies that reported data on the Stroop color word test in children and adults with ADHD and in age-matched controls; average ages ranged from 9 to 41 years. We utilized a hierarchical approach to analyze the strength of the Stroop effect and whether the effect varies as a function of age. Additionally, we assessed potential differences in maturation rates based on reaction time (RT) of color and color-word conditions. RESULTS First, we found that the relationship between color-word and color RT was multiplicative, and the slope of this function (the ratio of color-word RT over color RT) was identical across age groups and ADHD status. Second, we found that although ADHD individuals were on average 1.14 times slower than age-matched controls in both the color and the color-word condition, the maturation rate was identical for both groups. CONCLUSIONS The results from this analysis indicate that the Stroop interference effect is not larger in ADHD individuals than in age-matched controls. Further, we did not find evidence for differential maturation rates for persons with ADHD and the control groups. The Stroop interference effect appears to be immune to age, regardless of ADHD status.
Collapse
Affiliation(s)
- K Schwartz
- Department of Psychology, Center for Health and Behavior, Syracuse University, Syracuse, NY 13244, USA.
| | | |
Collapse
|
42
|
Stork H, Hamburger A, Gädke A, Fujara F, Schwartz K. Spatially resolved characterization of heavy ion irradiated crystals using static field gradient nuclear magnetic resonance. J Phys Condens Matter 2008; 20:275236. [PMID: 21694397 DOI: 10.1088/0953-8984/20/27/275236] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Static magnetic field gradient NMR has been used for one-dimensional spatial (19)F spin-lattice relaxation profile studies (resolution of the order of 10 µm) in a LiF crystal irradiated with U ions. Technical aspects of the use of large static magnetic field gradients are discussed as well as a special data acquisition mode allowing for effectively measuring spatially resolved spin-lattice relaxation rates as low as 10(-3) s(-1). In addition to the expected enhanced spin-lattice relaxation rate within the ion range, also an enhanced rate beyond the ion range has been found.
Collapse
Affiliation(s)
- H Stork
- Institut für Festkörperphysik, TU Darmstadt, Hochschulstraße 6, 64289 Darmstadt, Germany
| | | | | | | | | |
Collapse
|
43
|
Forissier JF, Charron P, du Montcel ST, Hagège A, Richard P, Desnos M, Schwartz K, Mousseaux E, Komajda M, Dubourg O. [Diagnostic value of a two-dimensional echocardiographic score for left ventricular hypertrophy validated by the Imatron CT scan in familial hypertrophic cardiomyopathy]. Arch Mal Coeur Vaiss 2006; 99:877-82. [PMID: 17100137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
The aim of this study was to validate a two-dimensional echocardiographic score for left ventricular hypertrophy in familial hypertrophic cardiomyopathy (HCM) by fast CT scan and to study the diagnostic value by an indexed threshold value in affected and genotyped families in comparison with the classical diagnostic method of maximal wall thickness (E max). The study was performed successively in two patient groups with HCM. The echo/CT scan population comprised 26 patients. They underwent echocardiography and Imatron CT scanning. The E max and 2D echo score (sum of the thickness of 4 segments) were measured by echocardiography and compared to the left ventricular mass obtained by the CT method. The 2D echo score was closely correlated to the CT left ventricular mass (r = 0.85) with a higher correlation coefficient than the E max (r = 0.78). The echo/generic population comprised 109 genotyped adults with an identified mutation. The E max and 2D echo score were measured. The genotype was the reference for diagnosis. A theoretical value of the 2D echo score was determined in healthy individuals by a multiple linear regression model of ages, sex and body surface area. A threshold value for abnormality was established after analysis of the ROC. The sensitivity and specificity were 63% and 100% respectively for E max and 73% and 96% respectively for the indexed 2D echo score. The improvement in sensitivity was marked in young adults (< 50 years) with 69% for the indexed 2D echo score versus 54% for E max, p < 0.04. The authors conclude that the indexed 2D score has been validated as an index of hypertrophy by the Imatron CT and has a better diagnostic value than E max, especially in young adults. This echocardiographic criterion could be proposed as an alternative diagnostic sign for screening families.
Collapse
Affiliation(s)
- J F Forissier
- Service de cardiologie, hôpital Ambroise-Paré, Boulogne.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Schwartz K, Nachman R, Yossifoff M, Sapir R, Weizman A, Rehavi M. Cocaine, but not amphetamine, short term treatment elevates the density of rat brain vesicular monoamine transporter 2. J Neural Transm (Vienna) 2006; 114:427-30. [PMID: 16897597 DOI: 10.1007/s00702-006-0549-8] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2006] [Accepted: 06/24/2006] [Indexed: 11/30/2022]
Abstract
We compared the effect of 5 days D-amphetamine (5 mg/kg/day i.p.) and cocaine (15 mg/kg/day i.p.) administration on the vesicular monoamine transporter 2 (VMAT2) density in rat brain. VMAT2 expression was assessed by [(3)H]dihydrotetrabenazine high affinity binding. Cocaine administration led to significant increases in VMAT2 density in both prefrontal cortex (+40%, p < 0.01) and striatum (+23%, p < 0.05), while amphetamine did not affect VMAT2 expression. The upregulation of VMAT2 may serve as compensatory mechanism aimed to enhance the vesicular monoamine storage capacity.
Collapse
Affiliation(s)
- K Schwartz
- Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | | | | | | | | | | |
Collapse
|
45
|
Schwartz K, Herman I, Peer G, Weizman A, Rehavi M. Elevated platelet vesicular monoamine transporter 2 in former heroin addicts maintained on methadone. J Neural Transm (Vienna) 2006; 114:281-4. [PMID: 16855915 DOI: 10.1007/s00702-006-0527-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2006] [Accepted: 05/08/2006] [Indexed: 11/25/2022]
Abstract
The brain vesicular monoamine transporter (VMAT2) is essential for neuronal monoamine storage and regulation of monoaminergic neurotransmission. We demonstrated previously a high degree of similarity between the pharmacodynamic characteristics of platelet and brain VMAT2. Opioids induce increase of dopamine release in limbic structures. In the present study we assessed the VMAT2 pharmacodynamic characteristics using high affinity [(3)H]dihydrotetrabenazine (TBZOH) binding to platelets of former male heroin addicts maintained on methadone (n = 12) compared to age-matched healthy controls (n = 13). A significant increase (19%, p < 0.05) in platelet VMAT2 density (Bmax) was observed in the methadone treated patients compared to controls. There was no significant difference in the affinity of [(3)H]TBZOH to its platelet binding site. The increased VMAT2 density may reflect a compensatory attempt to prevent vesicular depletion due to chronic methadone exposure.
Collapse
Affiliation(s)
- K Schwartz
- Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | | | | | | | | |
Collapse
|
46
|
Katz SJ, Hofer TP, Hawley S, Lantz PM, Janz NK, Schwartz K, Liu L, Deapen D, Morrow M. Correlates of patient referral to surgeons for treatment of breast cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.6032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6032 Background: Characteristics of surgeons and their practice settings have been associated with cancer treatments and outcomes. Yet, there is little information about factors that are associated with referral pathways to surgeons and treatment settings. Methods: We merged and analyzed tumor registry and survey data from all women with DCIS and a 20% random sample of women with invasive breast cancer diagnosed in 2002 and reported to the Detroit and Los Angeles SEER registries (N = 1,844, response rate 77.4%,) and their surgeons (N = 365, response rate 80.0%). Results: About half of the patients (54.2%) reported that they were referred to their surgeon by another provider or health plan; 20.3% reported that they selected their surgeon; 21.9% reported that they both were referred and were involved in selecting their surgeon; and the remaining patients (4.9%) reported that they had a prior relationship with their surgeon primarily through previous surgery. Selecting their surgeon based on reputation was more frequently reported by white patients (36.5% vs 26.5%, p < .001), and more highly educated patients (40.0% and 21.6%, respectively for highest and lowest education categories, p < .001). Patients who selected their surgeon based on reputation were more likely to have received treatment from a high volume surgeon (adjusted odds ratio 2.3; 95% CI 1.7, 3.2) and more likely to have been treated in an American College of Surgeon approved cancer program or NCI-designated cancer center (adjusted odds ratio 1.8; 95% CI 1.1, 2.8; 3.0 95% CI 1.6, 5.3, respectively). Patients who were referred to their surgeon were less likely to be treated in an NCI-designated cancer center (adjusted OR 0.4; 95% CI 0.2, 0.8). Conclusions: Women with breast cancer who actively participate in the surgeon selection process are more likely to be treated by more experienced surgeons and in hospitals with approved cancer programs. Patients should be aware that provider or health plan-based referral may not connect them with the most experienced surgeon or comprehensive practice setting in their community. An active patient role in the surgeon selection process has important implications for both the type of treatment received and where care is delivered. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. J. Katz
- University of Michigan, Ann Arbor, MI; Wayne State University, Detroit, MI; University of Southern California, Los Angeles, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - T. P. Hofer
- University of Michigan, Ann Arbor, MI; Wayne State University, Detroit, MI; University of Southern California, Los Angeles, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - S. Hawley
- University of Michigan, Ann Arbor, MI; Wayne State University, Detroit, MI; University of Southern California, Los Angeles, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - P. M. Lantz
- University of Michigan, Ann Arbor, MI; Wayne State University, Detroit, MI; University of Southern California, Los Angeles, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - N. K. Janz
- University of Michigan, Ann Arbor, MI; Wayne State University, Detroit, MI; University of Southern California, Los Angeles, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - K. Schwartz
- University of Michigan, Ann Arbor, MI; Wayne State University, Detroit, MI; University of Southern California, Los Angeles, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - L. Liu
- University of Michigan, Ann Arbor, MI; Wayne State University, Detroit, MI; University of Southern California, Los Angeles, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - D. Deapen
- University of Michigan, Ann Arbor, MI; Wayne State University, Detroit, MI; University of Southern California, Los Angeles, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - M. Morrow
- University of Michigan, Ann Arbor, MI; Wayne State University, Detroit, MI; University of Southern California, Los Angeles, CA; Fox Chase Cancer Center, Philadelphia, PA
| |
Collapse
|
47
|
Hawley S, Lantz P, Salem B, Fagerlin A, Janz N, Morrow M, Hofer T, Deapen D, Liu L, Schwartz K, Katz SJ. Patient and surgeon correlates of shared decision making for surgical breast cancer treatment. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.6031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6031 Background: The choice of surgical breast cancer treatment represents an opportunity for shared decision making (SDM), since both mastectomy and breast conserving surgery are viable options. Yet women vary in their desire for involvement in this decision. Correlates of SDM and/or the level of involvement in breast cancer surgical treatment decision-making are not known. Methods: Breast cancer patients of Detroit and Los Angeles SEER registries were mailed a questionnaire shortly after diagnosis in 2002 (N = 1,800, RR: 77%). Their responses were merged with a surgeon survey (N = 456, RR: 80%) for a dataset of 1,547 patients of 318 surgeons. Surgical treatment decision making was categorized into: 1) surgeon-based; 2) shared; or 3) patient-based. The concordance between a woman’s self-reported actual and desired decisional involvement was categorized as having more, less, or the right amount of involvement. Decision making and concordance were each analyzed as three-level dependent variables using multinomial logistic regression controlling for clustering within surgeons. Independent variables included patient clinical, treatment and demographic factors, surgeon demographic and practice-related factors, and a measure of surgeon-patient communication. Results: 37% of women reported the surgery decision was shared, 25% that it was surgeon-based, and 38% that it was patient-based. Two-thirds experienced the right amount of involvement, while 13% had less and 19% had more. Compared to women who reported a shared decision, those with surgeon-based decision were significantly (p < 0.05) more likely to have male surgeons, and those reporting a patient-based decision were more likely to have received mastectomy vs. breast conserving surgery. Women who were less involved in the surgery decision than they wanted were younger and had less education, while those with more involvement (vs. the right amount) more often had male surgeons. Patient-surgeon communication was associated with decisional involvement. Conclusions: Correlates of SDM and decisional involvement relating to surgical breast cancer treatment differ. Determining patients’ desired role in decision making may as important as achieving a shared decision for evaluating perceived quality of care. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Hawley
- University of Michigan, Ann Arbor, MI; Fox Chase Cancer Center, Philadelphia, PA; University of Southern California, Los Angeles, CA; Wayne State University, Detroit, MI
| | - P. Lantz
- University of Michigan, Ann Arbor, MI; Fox Chase Cancer Center, Philadelphia, PA; University of Southern California, Los Angeles, CA; Wayne State University, Detroit, MI
| | - B. Salem
- University of Michigan, Ann Arbor, MI; Fox Chase Cancer Center, Philadelphia, PA; University of Southern California, Los Angeles, CA; Wayne State University, Detroit, MI
| | - A. Fagerlin
- University of Michigan, Ann Arbor, MI; Fox Chase Cancer Center, Philadelphia, PA; University of Southern California, Los Angeles, CA; Wayne State University, Detroit, MI
| | - N. Janz
- University of Michigan, Ann Arbor, MI; Fox Chase Cancer Center, Philadelphia, PA; University of Southern California, Los Angeles, CA; Wayne State University, Detroit, MI
| | - M. Morrow
- University of Michigan, Ann Arbor, MI; Fox Chase Cancer Center, Philadelphia, PA; University of Southern California, Los Angeles, CA; Wayne State University, Detroit, MI
| | - T. Hofer
- University of Michigan, Ann Arbor, MI; Fox Chase Cancer Center, Philadelphia, PA; University of Southern California, Los Angeles, CA; Wayne State University, Detroit, MI
| | - D. Deapen
- University of Michigan, Ann Arbor, MI; Fox Chase Cancer Center, Philadelphia, PA; University of Southern California, Los Angeles, CA; Wayne State University, Detroit, MI
| | - L. Liu
- University of Michigan, Ann Arbor, MI; Fox Chase Cancer Center, Philadelphia, PA; University of Southern California, Los Angeles, CA; Wayne State University, Detroit, MI
| | - K. Schwartz
- University of Michigan, Ann Arbor, MI; Fox Chase Cancer Center, Philadelphia, PA; University of Southern California, Los Angeles, CA; Wayne State University, Detroit, MI
| | - S. J. Katz
- University of Michigan, Ann Arbor, MI; Fox Chase Cancer Center, Philadelphia, PA; University of Southern California, Los Angeles, CA; Wayne State University, Detroit, MI
| |
Collapse
|
48
|
Siddique M, Delano M, Schwartz K. Serum Ferritin May Not be a Reliable Predictor of Tissue Iron Concentrations. J Investig Med 2006. [DOI: 10.1177/108155890605402s05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Affiliation(s)
- M. Siddique
- Departments of Medicine and Radiology, Michigan State University, East Lansing, MI
| | - M.C. Delano
- Departments of Medicine and Radiology, Michigan State University, East Lansing, MI
| | - K. Schwartz
- Departments of Medicine and Radiology, Michigan State University, East Lansing, MI
| |
Collapse
|
49
|
Siddique M, Delano MC, Schwartz K. 5 SERUM FERRITIN MAY NOT BE A RELIABLE PREDICTOR OF TISSUE IRON CONCENTRATIONS. J Investig Med 2006. [DOI: 10.2310/6650.2005.x0015.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
50
|
Schwartz K, Weizman A, Rehavi M. The effect of psychostimulants on [3H]dopamine uptake and release in rat brain synaptic vesicles. J Neural Transm (Vienna) 2005; 113:1347-52. [PMID: 16362637 DOI: 10.1007/s00702-005-0383-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2005] [Accepted: 09/10/2005] [Indexed: 10/25/2022]
Abstract
Amphetamine and its derivatives are psychostimulants active at the plasma membrane monoamine transporters. In the present study we assessed the interaction of parachloroamphetamine, D-amphetamine, fenfluramine and methylendioxymethamphetamine with brain vesicular monoamine transporter using purified rat striatal synaptic vesicles. All four psychostimulants inhibited vesicular [(3)H]dopamine uptake in a competitive and dose-dependent manner and had no effect on [(3)H]dihydrotetrabenazine binding. At higher concentrations the drugs enhanced [(3)H]dopamine vesicular efflux. Parachloroamphetamine was the most potent agent while methylendioxymethamphetamine was the weakest one. The vesicular activities may be relevant to their neurotoxicity.
Collapse
Affiliation(s)
- K Schwartz
- Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | | | | |
Collapse
|